The management of colorectal cancer(CRC)poses a significant challenge,necessitating the development of innovative and effective therapeutics.Our research has shown that notoginsenoside Ft1(Ng-Ft1),a small molecule,mar...The management of colorectal cancer(CRC)poses a significant challenge,necessitating the development of innovative and effective therapeutics.Our research has shown that notoginsenoside Ft1(Ng-Ft1),a small molecule,markedly inhibits subcutaneous tumor formation in CRC and enhances the proportion of CD8^(+)T cells in tumor-bearing mice,thus restraining tumor growth.Investigation into the mechanism revealed that Ng-Ft1 selectively targets the deubiquitination enzyme USP9X,undermining its role in shieldingβ-catenin.This leads to a reduction in the expression of downstream effectors in the Wnt signaling pathway.These findings indicate that Ng-Ft1 could be a promising small-molecule treatment for CRC,working by blocking tumor progression via the Wnt signaling pathway and augmenting CD8^(+)T cell prevalence within the tumor environment.展开更多
目的探讨奥扎格雷钠联合阿加曲班对急性脑梗死(acute cerebral infarction,ACI)患者的应用效果及对血清脑源性神经因子(brain-derived neurofactor,BDNF)和血液流变学的影响。方法选取收治的ACI患者100例,随机均分为观察组(n=50)和对照...目的探讨奥扎格雷钠联合阿加曲班对急性脑梗死(acute cerebral infarction,ACI)患者的应用效果及对血清脑源性神经因子(brain-derived neurofactor,BDNF)和血液流变学的影响。方法选取收治的ACI患者100例,随机均分为观察组(n=50)和对照组(n=50)。对照组用奥扎格雷钠治疗,观察组在对照组治疗的基础上联合应用阿加曲班治疗,均持续治疗14 d。比较2组患者的临床疗效;采用美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评估患者的神经功能,采用格拉斯哥昏迷评分(Glasgow coma scale,GCS)评估患者的意识状况;比较2组患者的血液流变学指标;比较2组患者的BDNF和脑血管储备能力;比较2组患者治疗期间不良反应的发生率。结果治疗后,观察组患者的总有效率(96.00%)高于对照组(84.00%);观察组患者的NIHSS评分低于对照组(P<0.05),GCS评分高于对照组(P<0.05);观察组患者的全血高切黏度、全血低切黏度和血浆黏度均显著低于对照组(P<0.05);观察组患者的血清BDNF和脑血管储备能力均高于对照组(P<0.05);治疗期间2组不良反应发生率比较差异无统计学意义(P>0.05)。结论采用奥扎格雷钠联合阿加曲班治疗ACI有良好的的临床效果,可有效改善患者的血清BDNF和血液流变学水平。展开更多
基金supported by Shanghai Pujiang Program(No.20PJ1413000)the National Natural Science Foundation of China(No.82173106,82130115,81290108033,82004004,and 82074011)。
文摘The management of colorectal cancer(CRC)poses a significant challenge,necessitating the development of innovative and effective therapeutics.Our research has shown that notoginsenoside Ft1(Ng-Ft1),a small molecule,markedly inhibits subcutaneous tumor formation in CRC and enhances the proportion of CD8^(+)T cells in tumor-bearing mice,thus restraining tumor growth.Investigation into the mechanism revealed that Ng-Ft1 selectively targets the deubiquitination enzyme USP9X,undermining its role in shieldingβ-catenin.This leads to a reduction in the expression of downstream effectors in the Wnt signaling pathway.These findings indicate that Ng-Ft1 could be a promising small-molecule treatment for CRC,working by blocking tumor progression via the Wnt signaling pathway and augmenting CD8^(+)T cell prevalence within the tumor environment.
文摘目的探讨奥扎格雷钠联合阿加曲班对急性脑梗死(acute cerebral infarction,ACI)患者的应用效果及对血清脑源性神经因子(brain-derived neurofactor,BDNF)和血液流变学的影响。方法选取收治的ACI患者100例,随机均分为观察组(n=50)和对照组(n=50)。对照组用奥扎格雷钠治疗,观察组在对照组治疗的基础上联合应用阿加曲班治疗,均持续治疗14 d。比较2组患者的临床疗效;采用美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评估患者的神经功能,采用格拉斯哥昏迷评分(Glasgow coma scale,GCS)评估患者的意识状况;比较2组患者的血液流变学指标;比较2组患者的BDNF和脑血管储备能力;比较2组患者治疗期间不良反应的发生率。结果治疗后,观察组患者的总有效率(96.00%)高于对照组(84.00%);观察组患者的NIHSS评分低于对照组(P<0.05),GCS评分高于对照组(P<0.05);观察组患者的全血高切黏度、全血低切黏度和血浆黏度均显著低于对照组(P<0.05);观察组患者的血清BDNF和脑血管储备能力均高于对照组(P<0.05);治疗期间2组不良反应发生率比较差异无统计学意义(P>0.05)。结论采用奥扎格雷钠联合阿加曲班治疗ACI有良好的的临床效果,可有效改善患者的血清BDNF和血液流变学水平。
